Quality of life measures in lung cancer

Indian Journal of Cancer

Volumn 42, Issue 3, 2005, Pages 125-132

  Anant, Mohan ^a   Randeep, Guleria ^a   Ashutosh K, Pathak ^a   Manisha, Bhutani ^a   Hemraj, Pal ^a   Charu, Mohan ^a   Kochupillai, V ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Lung cancer; Performance status; Quality of life

Indexed keywords

ATTITUDE TO HEALTH; HUMAN; INSTRUMENTATION; LUNG TUMOR; PATHOPHYSIOLOGY; PROGNOSIS; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SICKNESS IMPACT PROFILE;

ATTITUDE TO HEALTH; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RISK ASSESSMENT; SICKNESS IMPACT PROFILE;

EID: 33644823354     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-509x.17056     Document Type: Review

References (45)

1. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC cancer base No. 5, IARC press: Lyon; 2001.
2. Ries LA, Kosary CL, Hankey BF. Lung and bronchus cancer: SEER Cancer Statistics Review, 1973-1996. National Cancer Institute: Bethesda, MD; 1999.
3. Cooley ME. Symptoms in adults with lung cancer: a systematic research review. J Pain Symptom Manage 2000;19:137-53.
4. Roila F, Cortesi E. Quality of life as a primary end point in oncology. Ann Oncol 2001;12:3-6.
5. Fayers PM, Jones DR. Measuring and analyzing quality of life in cancer clinical trials: a review. Stat Med 1983;2:429-46.
6. Montazeri A, Milroy R, Gillis CR, McEwen J. Quality of life: perception of lung cancer patients. Eur J Cancer 1996;32A:2284-9.
7. Gridelli C, Perrone F, Nelli F, Ramponi S, De Marinis F. Quality of life in lung cancer patients. Ann Oncol 2001;12:S21-5.
8. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J 1994;7:1350-64.
9. Geddes DM. Quality of life in lung cancer. Respir Med 1991;85:7-11.
10. Sarna L, Riedinger MS. Assessment of quality of life and symptom improvement in lung cancer clinical trials. Semin Oncol 2004;31:1-10.
11. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest 1998;113:467-81.
12. Bond A, Lader M. Use of analog scales in rating subjective feelings. Br J Med Psychol 1974;47:211-8.
13. Gift AG. Validation of a vertical visual analog scale as a measurement of clinical dyspnea. Rehab Nursing 1989;14:323-5.
14. Feld R. Endpoints in cancer clinical trials: is there a need for measuring quality of life? Support Care Cancer 1995;118:622-9.
15. Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose, and method of measurement. Cancer Invest 1993;11:327-36.
16. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.
17. Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, et al. What is a clinically meaningful change on the functional assessment of cancer therapy-lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology group (ECOG) Study 5592. J Clin Epidemiol 2002;55:285-95.
18. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
19. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on quality of life. Eur J Cancer 1994;30:635-42.
20. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, et al. Randomized phase III study of gemcitabinecisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999;17:12-8.
21. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, DeMarinis F, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 2000;18:3390-9.
22. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer. A randomized phase III study of the Italian lung cancer project. J Clin Oncol 1999;17:3522-30.
23. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 2001;31:233-40.
24. Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, et al. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-43.
25. Hollen PJ, Gralla RJ, Kris MG, Cox C. Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 1994;2:213-22.
26. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2000;18:2529-36.
27. Hollen PJ, Gralla RJ. Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 1996;23:31-40.
28. Hollen PJ, Gralla RJ, Kris MG, Eberly SW, Cox C. Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 1999;7:140-8.
29. Klastersky J, Paesmans M. Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer 2001;34:S95-101.
30. Svobodnik A, Yang P, Novotny PJ, Bass E, Garces YI, Jett JR, et al. Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis. Mayo Clin Proc 2004;79:1024-30.
31. nd edn. Lippincott-Raven: Philadelphia; 1996. p. 281-6.
32. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2000;92:1074-80.
33. Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. Br J Cancer 1995;71:633-6.
34. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editors. Evaluation of chemotherapeutic agents. Columbia University Press; New York; 1949. p. 191-205.
35. Schag CA, Ganz PA, Wing DS, Sim MS, Lee JJ. Quality of life in adult survivors of lung, colon, and prostate cancer. Qual Life Res 1994;3:127-41.
36. Schaafsma J, Osoba D. The Karnofsky performance status scales re-examined: a cross-validation with the EORTC-30. Qual Life Res 1994;3:413-24.
37. Zubrod CG, Scheiderman MA, Frei E. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960;11:7-33.
38. Buccheri GF, Ferrigno D. Karnofsky and ECOG performance status in lung cancer:equivalence, construct validity, and predictive validity (abstract). Lung Cancer 1994;11:S87.
39. Ganz PA, Lee JJ, Siau J. Quality of life assessment: an independent prognostic variable for survival in lung cancer. Cancer 1991;67:3131-5.
40. Ruckdeschel JC, Piantadosi S. Quality of life in lung cancer surgical adjuvant trials. Chest 1994;106:324-8.
41. Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 2000;55:19-25.
42. nd, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer 1999;85:333-40.
43. Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomized phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 1998;34:1036-44.
44. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999;91:66-72.
45. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-31.